Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conventional versus adalimumab-based biological treatment for Vogt-Koyanagi-Harada disease
ChiCTR2100043061Phase 3Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of adalimumab in Vogt-Koyanagi-Harada disease (VKH) (2 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Difference in mean ETDRS best-corrected visual acuity letter score at 26 weeks. Started Feb 2021; status: recruiting.
02
Drugs
03
Conditions
Vogt-Koyanagi-Harada disease (VKH)
Beyond the preview
Go deeper on ChiCTR2100043061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043061.